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adipose and heart CD36 RNA expression to inter-individual 
variability of postprandial lipid metabolism and document 
changes in CD36 DNA methylation that influence both CD36 
expression and lipids.—Love-Gregory, L., A. T. Kraja, 
F. Allum, S. Aslibekyan, Å. K. Hedman, Y. Duan, I. B. Borecki, 
D. K. Arnett, M. I. McCarthy, P. Deloukas, J. M. Ordovas, P. N. 
Hopkins, E. Grundberg, and N. A. Abumrad. Higher chylo-
micron remnants and LDL particle numbers associate with 
CD36 SNPs and DNA methylation sites that reduce CD36. 
J. Lipid Res. 2016. 57: 2176–2184.




Elevated fasting lipid levels have traditionally been asso-
ciated with increased risk of heart disease, diabetes, and 
stroke. More recently, similar and independent associa-
tions were found with levels of nonfasting or postprandial 
lipids (1, 2). Nonfasting measurements incorporate those 
of chylomicrons (CMs) produced in response to dietary fat 
Abstract Cluster of differentiation 36 (CD36) variants in-
fluence fasting lipids and risk of metabolic syndrome, but 
their impact on postprandial lipids, an independent risk fac-
tor for cardiovascular disease, is unclear. We determined the 
effects of SNPs within a 410 kb region encompassing CD36 
and its proximal and distal promoters on chylomicron (CM) 
remnants and LDL particles at fasting and at 3.5 and 6 h fol-
lowing a high-fat meal (Genetics of Lipid Lowering Drugs 
and Diet Network study, n = 1,117). Five promoter variants 
associated with CMs, four with delayed TG clearance and 
five with LDL particle number. To assess mechanisms under-
lying the associations, we queried expression quantitative 
trait loci, DNA methylation, and ChIP-seq datasets for adi-
pose and heart tissues that function in postprandial lipid 
clearance. Several SNPs that associated with higher serum 
lipids correlated with lower adipose and heart CD36 mRNA 
and aligned to active motifs for PPAR, a major CD36 regu-
lator. The SNPs also associated with DNA methylation sites 
that related to reduced CD36 mRNA and higher serum lip-
ids, but mixed-model analyses indicated that the SNPs and 
methylation independently influence CD36 mRNA.  The 
findings support contributions of CD36 SNPs that reduce 
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age (48.4 ± 16.3 years); BMI (28.3 ± 5.6 kg/m2); and blood pres-
sure  (systolic  115.3  ±  16.6 mmHg, diastolic  68.1  ±  9.3 mmHg) 












SNP selection and analysis
Genotype data for 81 SNPs within 410 kb (chr7: 79,900,000–
80,310,331) encompassing the CD36 gene region met quality con-
trol  procedures  and  were  used  to  impute  337  SNPs  based  on 
phased genotype data for HapMap CEU (release 22, Human Ge-
nome build 36) with MAFs 5% (28). SNP genotyping was per-
formed using the Affymetrix Human 6.0 platform (34). Linkage 




and adjusted for age, age2, and sex within a stepwise regression. 
Lead SNPs were tested against  lipid traits using the same linear 




(6 h post meal) (28). Bonferroni corrections for multiple tests 
(p  0.006) were based on the major variables, LDL, TG, and seven 
LD blocks, across the CD36 region (HapMap CEU, version 4.2).
Metabolic phenotype, transcript level, DNA methylation, 
and genotypes in the MuTHER cohort
The Multiple Tissue Human Expression Resource (MuTHER) 







tion  of  Illumina  arrays  (HumanHap300, HumanHap610Q,  1M 
Duo, and 1.2MDuo 1M) and imputed with IMPUTE (version 2) 
using  two reference panels, P0 (HapMap2, rel 22, combined 
CEU+YRI+ASN panels) and P1 (610k+, including the combined 
HumanHap610k and 1M array). The SNPs were filtered at MAF 
>5% and IMPUTE INFO value of >0.8.
The MuTHER study analyzed DNA methylation and transcript 
levels for 210,984 methylation and 18,818 expression probes situ-
ated on or 1,500 bp upstream of 13,532 genes. For this study, only 





ProbABEL packages. Age, beadchip, BS conversion efficiency, 
and  BS-treated  DNA  input  were  included  as  cofactors  in  the 
DNA methylation analysis (metQTL, Ntotal  = 603)  (37) and age 
and  experimental  batch  in  the  expression  analysis  [expression 
quantitative trait loci (eQTL), Ntotal = 776] (38), respectively. The 
cis-metQTL analysis was limited to SNPs within 100 kb on either 
ingestion. The TGs in CM particles are hydrolyzed by LPL 
in adipose, skeletal muscle, and heart vascular beds to 




thelial and parenchymal cells (7, 8). Elevated concentra-
tions of postprandial CM remnants after an oral fat load 
were  reported  in  four  subjects with complete CD36 defi-
ciency  (9),  suggesting  that  low  CD36  might  impair  CM 
clearance and result in sustained high levels of circulating 
CM remnants (10, 11). Studies support a heritable compo-
nent in determining postprandial lipid metabolism (12, 
13). A number of candidate genes were implicated, includ-
ing apolipoproteins and LPL, but together they account 
for a modest fraction of postprandial lipid variability (14).
CD36 is a highly conserved membrane protein expressed 
on metabolic and immune cells that functions in cellular 
recognition and uptake of many lipid-related molecules 
(15, 16), including dietary long chain fatty acids and native 
or oxidized lipoproteins (17). In addition, CD36 functions 
in transducing cell type-specific intracellular signaling that 
serves to regulate lipid utilization (17–19) or the immune 
response (20). Variants in the CD36 gene have been shown 
to influence fasting lipids (21, 22) and risk of metabolic 
syndrome  (MetS)  (22). Evidence  from CD36-null mouse 
models and CD36-deficient humans suggests that the pro-
tein regulates postprandial TGs and cholesterol metabo-
lism. In mice, CD36 deficiency increases cholesterol levels, 
impairs CM secretion into the lymph, and delays postpran-
dial TG clearance (9, 23–25). A similar phenotype is found 
in CD36-deficient subjects who were reported to have in-
creased CM  remnants  and  cholesterol  levels  (9,  26,  27). 
Despite  the  established  role  of CD36  in  lipid  absorption 
and CM metabolism, there is no information on whether 
polymorphisms in the CD36 gene influence variability in 
postprandial lipid metabolism in humans. Such informa-
tion is important considering the documented link be-
tween CM remnants and cardiovascular disease.
In  this  study,  we  determined  the  effects  of  common 
CD36 variants [minor allele frequency (MAF) 5–45%] on 
lipoprotein levels before and after ingestion of a high-fat 
shake in the family-based study of 1,117 Caucasian partici-
pants,  the Genetics of Lipid Lowering Drugs and Diet 
Network (GOLDN) (28). We identified several SNPs that 
influence CM remnants, TG response, and LDL. The most 
significant  SNPs  overlap  those  previously  associated  with  
MetS. Examination of the potential mechanisms underly-
ing the observed effects highlighted transcriptional and 
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phenotype effect  in each model was  calculated  from  the Chi-
square distribution with 1° of freedom using 2log (likelihood 
ratio) as the test statistic.
RESULTS
Common CD36 SNPs influence CM remnants and TG 
levels
The GOLDN cohort includes relatively healthy over-
weight to obese individuals (as indicated in the Materials 
and Methods). The plasma lipid profile for this cohort 
before and after the meal is in supplemental Table S1. To 
comprehensively  examine  the  effects  of  common  CD36 
variants on postprandial lipids, we tested SNPs across the 
CD36  locus  encompassing  all  six  alternative  first  exons 
(1A–1F)  (41,  42)  and  the  two  3′UTRs (short and long) 
(Fig. 1).  SNP associations with CM  levels were  identified 
(Table 1, Fig. 1) at 3.5 and 6 h post meal. At 3.5 h, indepen-




meal,  the  same  relationships  were  maintained  for  SNPs 
rs10081383 and rs37920 (Fig. 1B, Table 1). The effect of 
rs37920 (C allele) was much more significant at 6 h, sug-
gesting that the major impact of the allele is to reduce 







to p < 8.6E-4, p < 5.0E-5, and p < 2.6E-4, respectively.





efficiency, and BS-treated DNA input) and random effects (family 
relationship and zygosity). A likelihood ratio test was used to 
assess significance of the phenotype effect. The p value of the 
Fig. 1.  SNPs near distal first exon 1D of CD36 associ-
ate with CM remnants. Regional plot of CD36 SNPs 
that associate with CM remnant concentration at 3.5 h 
(A) and 6 h (B) after a the fat meal. p values (log10) 
are plotted based on chromosomal position (human 
genome  GRCh37/hg19).  Colors  differentiate  LD 
blocks (r2  0.8). The most significant SNP (represen-
tative tag SNP) is identified by a larger symbol and the 
rs identification number. The overlay of the CD36 
gene from the UCSC genome browser illustrates the 
SNP position relative to alternative CD36 promoters 
and transcripts (referred to as 1B, 1C, 1D) and the 
long 3′UTR (asterisk). Dotted red lines indicate p  
0.05 and the Bonferroni-corrected threshold, p < 
0.006.
TABLE 1. CD36 tag SNPs influence CM levels
SNP Effect Allele MAF  (SE) pa
3.5 h post meal
  rs10081383 G/A 0.24 0.18 (0.06) 0.0035
  rs37920 T/C 0.07 0.40 (0.14) 0.0034
  rs2048474 A/G 0.32 0.19 (0.06) 0.0011
  rs13230620 G/C 0.28 0.18 (0.06) 0.0032
6.0 h post meal
  rs10081383 G/A 0.24 0.18 (0.06) 0.0005
  rs37920 T/C 0.07 0.57 (0.14) 0.00003
  rs12535593 T/C 0.27 0.26 (0.07) 0.0002
Shown  are -estimates ()  ±  SEs  and  raw  p values for the most 
significant CD36  tag SNP (within respective LD blocks)  that associate 
with CM levels. SNPs are listed based on genomic positions (see Fig. 1). 
The effect allele is bold and underlined.
a Bonferroni correction threshold p < 0.006.
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exon 1C) and proximal (near 1B) promoters and  in  the 
longer  3′UTR. The most  significant  observations were 
with tag rs1761665 (C-allele, 44%) and rs6970109 (A-allele, 





post meal, but this did not survive the Bonferroni correc-
tion. Of note,  the associations  shown  for  fasting LDL re-
mained significant at 3.5 and 6 h post meal (supplemental 
Table S2) as would be expected.
Lipid-associated SNPs influence CD36 mRNA levels in 
adipose tissue and heart
To determine the potential functional relevance of 
the lipid-associated SNPs, we examined their influence on 
CD36 level in adipose and heart, tissues that are highly 
active  in  lipid metabolism and where CD36  is  abundant. 
eQTL were available  for adipose  tissue  from 776 healthy 
individuals of  the MuTHER project  (38). As  shown  in 








relationships between  the  lipid-SNPs and CD36 mRNA 
(Table 4). These findings document strong effects of  the 
SNPs on CD36 transcripts in heart and adipose tissue and 
suggest that expression in these tissues inversely relates to 
higher lipids, consistent with the role of CD36 in enhanc-
ing lipid clearance and reducing circulating lipid levels.















clearance (3.5–6.0 h) phases. As shown in Table 2, three 




rs37920  associated  with  higher  CM  remnants  (Table  1), 
which is consistent with slow TG removal (Table 2). These 
findings support a role for the distal 1D region of CD36 in 
the regulation of postprandial lipid metabolism.
LDL
Associations with higher LDL particle numbers at fasting 
and at the post meal times (Fig. 2, Table 3, supplemental 
Table 2) were identified for SNPs in the central (near first 
TABLE 2. Effect of CD36 SNP on growth curve slopes for TG 
appearance (0–3.5 h) and clearance (3.5–6.0 h) after the meal
SNP Effect Allele MAF  (SE) pa
0–3.5 h
  rs304763 G/A 0.38 0.15 (0.05) 0.0049
  rs304798 A/G 0.21 0.21 (0.07) 0.0019
  rs304802 T/C 0.32 0.20 (0.06) 0.0009
3.5–6.0 h
  rs37920 T/C 0.07 0.44 (0.13) 0.0008
  rs13228738 G/A 0.38 0.16 (0.05) 0.0032
  rs1931694 G/C 0.47 0.15 (0.05) 0.0048
  rs3211842 G/A 0.42 0.17 (0.05) 0.0013
Shown  are  -estimates ()  ±  SEs  and  raw  p-values for the most 
significant CD36 tag SNP (within respective LD blocks). The effect allele 
is bold and underlined. For TG appearance, negative -estimates indicate 
that the allele reduces absorption. For clearance, negative  indicates 
enhanced TG removal and positive  indicates reduced TG removal.
a Bonferroni correction threshold p < 0.006.
Fig. 2. CD36 SNPs in the proximal and central pro-
moter  regions  associate  with  fasting  LDL.  p-values 
(log10) are plotted based on chromosomal position 
(human  genome  GRCh37/hg19).  Colors  differenti-
ate LD blocks (r2  0.8) with the most significant SNP 
(representative tag) identified by a larger symbol and 
rs identification number. Dotted red lines indicate 
p  0.05 and Bonferroni threshold, p < 0.006.
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most  abundant CD36  transcript  (1B with  long 3′UTR). 
This indicated that the effect of the SNPs on CD36 is inde-
pendent of methylation at the above sites and is more likely 
to involve transcriptional regulation of the gene by PPAR 
or posttranslational regulatory sites in the 3′UTR (rs7755). 
We then examined whether methylation also relates to 
higher lipid levels. As shown in Table 7, DNA methylation 
correlated with higher TG and LDL, suggesting that it in-




factors can lead to sustained elevation of postprandial lip-
ids, which independently increases the risk of cardiovas-




tant role in etiology of MetS and cardiovascular disease, 
remains limited. This study is the first comprehensive ex-
amination of the impact of CD36 variants on postprandial 
lipids. We present findings implicating common promoter 
SNPs in inter-individual variability of the CM remnant re-
sponse after a fatty meal. We also identify SNPs that as-
sociate with LDL particle number at both fasting and two 













CD36 transcriptional regulator (Fig. 3). In addition, this 
region is characterized by active histone H3 lysine methyla-
tion and acetylation marks (46).




tested  to  determine whether  a  significant  relationship 
exists  between  the  lipid-associated  SNPs we  identified  and 
methylation using a multivariate linear regression model 
with age and BMI as covariates. Interestingly, the lipid-SNPs 




Hypomethylation of four of these sites strongly related to 
CD36 mRNA levels (Table 6). To gain a better perspective 
of the contribution of altered methylation to the SNP 






strates that adjustment for methylation does not signifi-
cantly attenuate the associations between the SNPs and the 
TABLE  3.  CD36 tag SNPs associate with higher LDL
SNP Effect Allele MAF  (SE) pa
rs6970109 C/A 0.10 0.26 (0.09) 0.0027
rs1722507c A/G 0.39 0.17 (0.05) 0.0011
rs1761665b,c T/C 0.44 0.20 (0.05) 0.0001
rs3211842b G/A 0.42 0.02 (0.05) 0.0017
rs7755d G/A 0.46 0.16 (0.05) 0.0020
SNPs are listed by genomic location. The effect allele is bold and 
underlined. Shown are -estimates () ± SEs and raw p-values for most 
significant CD36 tag SNP (within respective LD blocks). Data shown are for 
fasting LDL. Supplemental Table S2 shows data for 3.5 and 6 h post meal.
a Bonferroni correction threshold p < 0.006.
b LD between SNPs: r2 > 0.80, D′ = 0.93.
c LD between SNPs: r2 = 0.68, D′ = 1.0.




 (SE) p  (SE) p
rs1931694 (TGc) G/C 0.17 (0.03) 1.24 × 1009 — —
rs1722507c (TGc) A/G 0.25 (0.03) 5.58 × 1017 — —
rs1761665b (LDL) T/C 0.27 (0.03) 3.31 × 1022 0.40 (0.08) 7.25 × 107
rs13228738c (TGc) G/A 0.24 (0.03) 1.03 × 1016 — —
rs3211842b (TGc) G/A 0.28 (0.03) 2.27 × 1022 — —
rs7755 (LDL) G/A 0.44 (0.03) 1.12 × 1050 0.53 (0.08) 4.32 × 1011
Correlations between alleles and CD36 mRNA were determined using  simple  regression. SNPs are  listed by 
effect size. Frequency of the effect allele is 40% for all listed SNPs. The effect allele is bold and underlined. The 
lipid trait affected by the SNP is in parentheses: SNPs are listed based on genomic location. CD36 mRNA levels 
(ILMN_1784863; Illumina HT-12 v3) in abdominal subcutaneous adipose tissue in the MuTHER were retrieved from 
GENEVAR database. TGc, TG clearance.
a SNP effects on heart CD36 expression (ILMN_1784863; Illumina HumanHT-12 v4) from a genome wide eQTL 
dataset in nondiseased tissue of 129 Western Europeans (45).
b SNPs in LD: r2 > 0.80, D′ > 0.8.
c SNPs in LD: r2 = 0.93, D′ > 0.8.
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(52). We queried available Global Lipid Genetics Consor-
tium datasets using LocusZoom and found that most co-
horts did not include sufficient SNP coverage of the CD36 
promoter region comparable to this study. In one of the 




rs6949840,  rs2030711,  and  rs17154155,  are  in  strong LD 
with  rs1722507  and  rs1761665  in  this  study.  In  addition, 
our study measured LDL particle number as opposed to 
LDL  cholesterol  obtained  by  the  Friedewald  calculation. 
While both measures predict cardiovascular risk, they do 
not always correlate (1, 54). In support of our findings are 




LDL particle response to fenofibrate treatment in GOLDN 





support  an  important  role  of CD36  in  the handling  of 
dietary  lipids  in  humans  and  are  consistent with  data  in 
CD36-null  mice  showing  defective  CM  metabolism  and 




to variability of the postprandial response and possibly to 
risk of diet-induced metabolic abnormalities. GOLDN is 
the largest cohort to-date in which postprandial lipid mea-
sures are available and, ideally, our findings will need repli-
cation in other large studies as they become available.
We identified five CD36  SNPs  to  associate with higher 
LDL, while previous GWASs did not link LDL to the CD36 
locus.  Several  considerations  might  explain  the  discrep-




of ages, metabolic disease traits, medications, and BMI 
TABLE  5.  Lipid-SNPs associate with DNA methylation in adipose tissue
CpG ID rs13228738 rs3211842 rs1722507 rs1761665 rs7755
cg18508525a 9.65 × 1006 3.83 × 1004 2.76 × 1007 3.20 × 1005 3.04 × 1004
cg25783969a 1.24 × 1008 — 7.23 × 1011 6.72 × 1005 9.26 × 1005
cg21055948a 1.57 × 1011 5.01 × 1006 2.37 × 1013 3.08 × 1007 6.14 × 1006
cg19096849 3.36 × 1009 5.87 × 1006 3.64 × 1011 1.40 × 1007 7.97 × 1007
cg26138637a — — 8.38 × 1005 — —
cg06601993 — — 6.75 × 1004 4.00 × 1004 —
Adipose tissue CpG methylation levels determined in the MuTHER study using the Infinium HumanMethylation450 
platform. CpGs listed based on chromosomal position. p-values are for CpG-SNP associations.
a CpG associates with adipose CD36 mRNA (Table 6).
Fig. 3. TG clearance and LDL-associated CD36 
SNPs align in proximity to PPAR motifs and to CpG 
sites in the CD36 promoter. The central CD36 pro-
moter region (chr7: 80,060,000–80,095,000) is tagged 
by rs1761665, which associates with methylation levels 
at CpG sites in adipose tissue near CD36 alternative 
exon 1C that is specific to adipocytes (absent from im-
mune cells and endothelial cells). A: Purple text indi-
cates  SNPs  that  associate  with  both  lipid  levels  and 
adipose  tissue  CD36  expression.  B:  SNP-associated 
methylation sites (red text). The location of a previ-
ously  published  TG-associated  CpG  site  is  shown  in 
blue text (47). C: Chromatin state maps of the CD36 
locus from mature human adipocytes. Histograms of 
ChIP-seq  fragments aligned to  the human reference 
genome (hg18) highlighting active PPAR binding 
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